A spate of recent examples indicates that inversion transactions are as popular as they have ever been, with Pfizer’s attempted deal with AstraZeneca highlighting that companies in the pharmaceuticals industry are increasingly using the inversion option. William Fry Tax Advisors, the Irish member firm of Taxand, look at why this is, and analyse why Ireland is proving to be the location of choice for newly-formed companies post-inversion.
To view the full article which appeared in this months International Tax Review Special Feature please click here.
Recommended Insights
Article and Insights
1
Feb 2024
William Fry is pleased to launch its Responsible Business Annual Report 2023.
Article and Insights
2
Feb 2024
We focus on the second batch of draft implementation measures announced by the Eur...
Partner
John O’Connor
Article and Insights
2
Feb 2024
The Supreme Court has refused leave to appeal from a decision rejecting John Delan...
Consultant
Deirdre O’Donovan
Article and Insights
24
Jan 2024
The High Court recently dismissed a petition seeking the winding up of a biofuel c...
Partner
Fergus Doorly
prev
next